BIOMAT Database Logo BIOMAT Database Logo

Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs. 2020

Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
Laboratory of Experimental Hematology, Department of Haematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Brussels, Belgium.

BACKGROUND In addition to their roles in different biological processes, microRNAs in the tumor microenvironment appear to be potential diagnostic and prognostic biomarkers for various malignant diseases, including acute myeloid leukemia (AML). To date, no screening of circulating miRNAs has been carried out in the bone marrow compartment of AML. Accordingly, we investigated the circulating miRNA profile in AML bone marrow at diagnosis (AMLD) and first complete remission post treatment (AMLPT) in comparison to healthy donors (HD). METHODS Circulating miRNAs were isolated from AML bone marrow aspirations, and a low-density TaqMan miRNA array was performed to identify deregulated miRNAs followed by quantitative RT-PCR to validate the results. Bioinformatic analysis was conducted to evaluate the diagnostic and prognostic accuracy of the highly and significantly identified deregulated miRNA(s) as potential candidate biomarker(s). RESULTS We found several deregulated miRNAs between the AMLD vs. HD vs. AMLPT groups, which were involved in tumor progression and immune suppression pathways. We also identified significant diagnostic and prognostic signatures with the ability to predict AML patient treatment response. CONCLUSIONS This study provides a possible role of enriched circulating bone marrow miRNAs in the initiation and progression of AML and highlights new markers for prognosis and treatment monitoring.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074166 Circulating MicroRNA MicroRNAs found in cell-free BODY FLUIDS such as SERUM; PLASMA; SALIVA; OR URINE. Cell-Free MicroRNA,Cell Free MicroRNA,MicroRNA, Cell-Free,MicroRNA, Circulating
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments

Related Publications

Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia.
January 2013, PloS one,
Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
Identification of NPMc+ acute myeloid leukemia in bone marrow smears.
January 2013, Applied immunohistochemistry & molecular morphology : AIMM,
Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
Bone marrow transplant in acute myeloid leukemia.
August 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
Autologous bone marrow transplantation for acute myeloid leukemia.
January 1996, Stem cells (Dayton, Ohio),
Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
MicroRNAs of bone marrow mesenchymal stem cell-derived exosomes regulate acute myeloid leukemia cell proliferation and apoptosis.
December 2020, Chinese medical journal,
Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
[Bone marrow cultures from patients with acute myeloid leukemia].
December 1988, Lijecnicki vjesnik,
Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
[Bone marrow transplants for patients with acute myeloid leukemia].
February 1981, Nederlands tijdschrift voor geneeskunde,
Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia.
January 2021, Frontiers in cell and developmental biology,
Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
Hypocellular acute myeloid leukemia treated with bone marrow transplantation.
April 2017, Pediatrics international : official journal of the Japan Pediatric Society,
Douâa Moussa Agha, and Redouane Rouas, and Mehdi Najar, and Fatima Bouhtit, and Najib Naamane, and Hussein Fayyad-Kazan, and Dominique Bron, and Nathalie Meuleman, and Philippe Lewalle, and Makram Merimi
Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines.
January 2013, Revista brasileira de hematologia e hemoterapia,
Copied contents to your clipboard!